

Ondansetron

Form:	4mg in 2ml ampoule 8mg in 4ml ampoule
Reconstitution:	Already in solution
Administration Method:	<p><u>IV Injection</u> Administer over 3 - 5 minutes.</p> <p><u>Intermittent IV Infusion</u> Add required dose to 50 - 100ml compatible fluid and infuse over 15 minutes.</p> <p><u>Continuous IV Infusion</u> Add dose to 50 - 100ml compatible fluid and administer at a rate of 1 mg/hour for up to 24 hours.</p> <p><u>IM Injection</u> No further dilution required.</p>
Compatibility & Stability:	Sodium Chloride 0.9% Glucose 5%
Special Notes:	<ul style="list-style-type: none"> • Ondansetron may cause QT prolongation. • Hypokalaemia and hypomagnesaemia should be corrected prior to administration of ondansetron.

Information provided relates to Ondansetron 2mg/ml manufactured by Claris Lifesciences and Zofran[®] manufactured by Novartis.

This information has been summarised to act as a guide for those administering IV medication. The monograph should be used in conjunction with the drug data sheet and BNF for information on dose, adverse effects, cautions and contra-indications. Further information is available from Pharmacy on 22146 or 22542